Genetic data adds a new angle to Madrigal Pharmaceuticals
Madrigal Pharmaceuticals (MDGL) has introduced new data into the MASH debate after publishing a secondary MAESTRO-NASH analysis that examined Rezdiffra’s efficacy across several common genetic risk variants associated with disease progression.
Madrigal Pharmaceuticals has seen its short term share price momentum cool, with the stock down 16.4% year to date and 12.2% over the past quarter. Even so, the 1 year total shareholder return of 13.8% and 3 year total shareholder return of over 3x suggest longer term holders have still been well rewarded.
Capitalize on the genetic medicine momentum around Madrigal Pharmaceuticals by scanning a curated set of 34 healthcare AI stocks that could benefit as data and biology increasingly intersect.Madrigal Pharmaceuticals appears to have a clear drug, a focused indication and fresh genetic data in its corner. Following a sharp pullback in the share price, the question is whether that strength is already reflected in the US$496 price.
Most Popular Narrative: 27% Undervalued
Against Madrigal Pharmaceuticals' last close at $496.45, the most followed narrative pins fair value closer to $678.71. This frames the recent pullback as a valuation gap rather than a verdict on the Rezdiffra story.
The rapid uptake and long-term patent protection of Rezdiffra, supported by a new U.S. patent that extends exclusivity to 2045, provides decades of protected revenue opportunity. This increases the likelihood of sustained top-line growth and supports margin expansion due to extended pricing power.
See why 14 investors see Madrigal Pharmaceuticals as 27% undervalued.
Result: Fair Value of $678.71 (UNDERVALUED)
Still, Madrigal Pharmaceuticals depends heavily on Rezdiffra. Any slower than expected MASH uptake or tougher payer discounts could quickly challenge that undervaluation story.
Find out about the key risks to this Madrigal Pharmaceuticals narrative.
Next Steps
Mixed messages around Madrigal Pharmaceuticals often leave investors split. With both material risks and genuine bright spots in play, it is important to scrutinize the evidence yourself and pressure test your view against the 3 key rewards and 1 important warning sign.
Looking for more Madrigal Pharmaceuticals investment ideas?
If Madrigal Pharmaceuticals has sharpened your interest in where capital and healthcare could intersect next, do not leave potential opportunities sitting unseen on the sidelines. Use the Simply Wall Street Screener to quickly surface focused ideas that match your risk comfort and return goals, instead of relying on headlines and hype alone.
- Target quality at a discount by scanning a curated pool of 27 high quality undervalued stocks that already combine strong fundamentals with appealing prices.
- Prioritize resilience in choppy markets and review a 31 resilient stocks with low risk scores that may help you keep downside in check while you stay invested.
- Get ahead of the crowd by hunting through a 19 high quality undiscovered gems before wider attention starts to close the gap between price and potential.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com